Moteur de recherche d’entreprises européennes
Financement de l’UE (160 800 €) : Synthèse de produits pharmaceutiques Spirooxindoles et INdoles à l’aide de structures organométalliques Hor17/03/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Synthèse de produits pharmaceutiques Spirooxindoles et INdoles à l’aide de structures organométalliques
SINMOF is a pioneering and structured effort to comprehensively address the introduction of different immobilised isolated catalytic active sites in solid hybrid materials to overcome the metal losses occurring with state-of-the-art homogeneous catalysts employed in the pharmaceutical industry. The convenient use of hybrid metal-organic framework materials (MOFs) respect to traditional state-of-the-art porous solid materials is due to (a) self-deactivation-resistant design of the active sites by (b) ultrastable catalytic site isolation. In the SINMOF project we will (1) design novel multifunctional MOFs as next generation catalysts for the synthesis of pharmaceutically active compounds in an economically and environmentally beneficial way; (2) apply MOF hybrid solids as heterogeneous catalysts to avoid the use of homogeneous metal catalysts in novel synthetic strategies of pharmaceuticals with the indole core and finally (3) derive structure-activity and selectivity relationships at the smallest possible length scales and with the highest possible sensitivities employing fluorescence microscopy. Using a two-stage research methodology, SINMOF will finally provide the most active and stable MOF catalyst for the synthesis of the indole-based neurotransmitter Sumatriptan and the anticancerigen spirooxindole SAR405838. The combined expertise of the fellow and host ensures the best chance for successfully completing the SINMOF objectives in a mutually beneficial manner. On one side, internal collaborations at the host institution will allow the access to state-of-the-art fluorescence microscopy methods, to get new insights into the molecular mechanisms underlying the novel catalytic systems. On the other side, a secondment at a world-leading research center in the homogeneous catalysis field will train the researcher in order to individuate the best molecular features for model homogeneous catalysts to be translated into selective heterogeneous MOF catalytic system.
| Katholieke Universiteit Leuven | 160 800 € |
https://cordis.europa.eu/project/id/750391
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Katholieke Universiteit te Leuven, Leuven, Belgique.
Les visualisations de "Katholieke Universiteit Leuven - Financement de l’UE (160 800 €) : Synthèse de produits pharmaceutiques Spirooxindoles et INdoles à l’aide de structures organométalliques"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
